Vineet Laboratories Ltd. (VINEETLAB) AI Stock Analysis

Vineet Laboratories Ltd.

(NSE:VINEETLAB)

Select Model

Rating:47Neutral

Price Target:INR 34.00▼(-8.36% Downside)

Action:reiterated

Date:08/29/26

The overall score is held down mainly by weak and volatile financial performance, including shrinking revenues and inconsistent cash generation, partially offset by a healthier 2026 margin and capital structure, while moderately positive technical momentum offers some support but the high, yield-free valuation limits risk-adjusted upside.

Positive Factors

Earnings RecoveryThe move from a deep 2025 loss to positive net margin, alongside stronger operating margins, shows a meaningful earnings recovery. This improves internal funding potential and demonstrates that the business can restore profitability, although the still-thin margin means durability remains to be proven.

Negative Factors

Weak Cash GenerationLarge negative operating and free cash flow in 2026 indicate that reported earnings are not converting reliably into liquidity. Persistent cash deficits can increase reliance on financing, constrain investment capacity, and leave the company more exposed when demand or profitability weakens.

Vineet Laboratories Ltd. (VINEETLAB) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 729.65M
Dividend Yield: ―
Average Volume (3M): 34.50K
Price to Earnings (P/E): 15.1
Beta (1Y): 0.66
Revenue Growth: 6.45%
EPS Growth: ―
Country: India
Employees: 57
Sector: General
Sector Strength: 55
Industry: Chemicals - Specialty

Vineet Laboratories Ltd. Business Overview & Revenue Model

Company Description

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavir...

Vineet Laboratories Ltd. Financial Statement Overview

Summary

Revenue has shrunk sharply over the period, profits are highly volatile with a very weak year in 2025, and cash flows are frequently negative, with only modest margin and balance-sheet improvement in 2026 supporting the score.

Income Statement

38Negative

Balance Sheet

44Neutral

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Jun 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	594.01M	594.01M	749.95M	1.51B	2.12B	1.91B
Gross Profit	159.67M	142.82M	-124.68M	139.85M	399.65M	454.26M
EBITDA	85.53M	84.79M	-142.96M	67.32M	77.83M	134.47M
Net Income	11.11M	11.11M	-201.91M	10.27M	12.53M	66.39M
Balance Sheet
Total Assets	1.25B	1.25B	945.40M	1.17B	1.16B	1.34B
Cash, Cash Equivalents and Short-Term Investments	170.75M	170.75M	6.69M	2.28M	6.31M	181.17M
Total Debt	453.25M	453.25M	400.47M	443.00M	310.89M	307.04M
Total Liabilities	791.81M	791.81M	798.92M	821.48M	821.66M	1.00B
Stockholders Equity	456.02M	456.02M	146.48M	347.24M	336.83M	332.18M
Cash Flow
Free Cash Flow	771.00K	-180.10M	104.46M	-116.61M	-172.50M	77.15M
Operating Cash Flow	771.00K	-168.13M	114.91M	-114.27M	-96.16M	77.15M
Investing Cash Flow	-371.00K	-12.14M	-31.82M	-22.22M	-66.86M	-35.72M
Financing Cash Flow	-651.00K	346.29M	-82.30M	84.30M	2.73M	119.55M

Vineet Laboratories Ltd. Technical Analysis

Technical Analysis SentimentPositive

Last Price37.10

Price Trends

50DMA37.20Negative

100DMA36.53Positive

200DMA34.90Positive

Market Momentum

MACD0.00Positive

RSI49.68Neutral

STOCH27.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VINEETLAB, the sentiment is Positive. The current price of 37.10 is below the 20-day moving average (MA) of 37.45, below the 50-day MA of 37.20, and above the 200-day MA of 34.90, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 49.68 is Neutral, neither overbought nor oversold. The STOCH value of 27.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VINEETLAB.

Vineet Laboratories Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:VINEETLAB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:INDOAMIN	76Outperform	INR 8.68B	10.73	―	0.42%	13.23%	22.22%
IN:PRIMO	69Neutral	INR 5.46B	34.63	―	―	-2.70%	-15.41%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:DMCC	53Neutral	INR 6.34B	15.85	―	0.98%	72.14%	34.49%
IN:VINEETLAB	47Neutral	INR 712.55M	15.07	―	―	6.45%	―
IN:DIAMINESQ	43Neutral	INR 2.26B	-22.12	―	0.45%	-27.77%	-61.55%
IN:ISHANCH	37Underperform	INR 1.22B	50.02	―	―	84.25%	―

* General Sector Average

Performance Comparison

IN:VINEETLAB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:VINEETLAB	Vineet Laboratories Ltd.	37.10	-2.31	-5.86%
IN:DIAMINESQ	Diamines & Chemicals Ltd.	224.35	-45.25	-16.78%
IN:DMCC	DMCC Speciality Chemicals Limited	254.25	-45.46	-15.17%
IN:INDOAMIN	Indo Amines Limited	119.55	-12.92	-9.75%
IN:PRIMO	Primo Chemicals Limited	22.53	-0.73	-3.14%
IN:ISHANCH	Ishan Dyes and Chemicals Limited	44.68	-28.65	-39.07%

Vineet Laboratories Ltd. Corporate Events

Vineet Laboratories Claims SEBI Corporate Governance Exemption for June Quarter

Jul 30, 2026

Vineet Laboratories Ltd. has formally notified the BSE and NSE that corporate governance compliance requirements under Regulation 27(2) of SEBI’s Listing Obligations and Disclosure Requirements are not applicable for the quarter ended June 30,...

Vineet Laboratories Strengthens Board With Appointment of Executive Director Rajesh Kumar Kathulla

Jul 21, 2026

Vineet Laboratories Ltd. has announced a change in its board composition with the appointment of Hyderabad-based entrepreneur Rajesh Kumar Kathulla as an Additional Executive Director, effective 11 June 2026. His five-year term is subject to sharehol...

Vineet Laboratories Redesignates Promoter Ramana as Non-Executive Director

Jul 21, 2026

Vineet Laboratories Ltd. has announced that Managing Director Mr. Gaddam Venkata Ramana will cease to hold the MD position effective July 21, 2026. He remains on the board as a director and is being redesignated as a non-executive director, while con...

Vineet Laboratories Sets Board Meet to Approve FY26 Results, Keeps Trading Window Shut

Jul 11, 2026

Vineet Laboratories Ltd. has scheduled a board meeting on July 15, 2026, to consider and approve its audited standalone financial results for the fourth quarter and the financial year ended March 31, 2026. This step underscores the company’s ad...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 29, 2026

Vineet Laboratories Ltd. AI Stock Analysis